ResMed Inc. (RMD) Stock: Price, Forecast & Analyst Target
ResMed Inc. (RMD) — MoonshotScore 95/100 (Exceptional band), calculated Nov 18, 2026. Price $242.61 (+2.00%), as of the Nov 18, 2026 trading session; market cap $34.1B. Expected results Jan 28, 2027.
Educational signal · not a buy or sell recommendation · How to read this
ResMed Inc. · RMD · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-12: ResMed sells sleep and respiratory devices, masks and accessories, then connects them to patient-monitoring software and a smaller out-of-hospital care platform. Its durability depends on whether that combined ecosystem can keep expanding while portfolio changes and renewed margin pressure interrupt the recent profit trajectory.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · ResMed (RMD)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 7 of the last 8 reports
- expected results Jan 28, 2027
- Altman Z 11.99 · Piotroski F 7
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 95 | Exceptional | |
| 90 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional | |
| 95 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $242.61 | |
| Change on the day | +2.00% | |
| 52-week range | $180.27–$277.67 | |
| Market capitalisation | $34.1B | — |
| Price / earnings (trailing) | 21.60 | |
| Shares traded on the day | 1.22M | |
| Beta (volatility vs the S&P 500) | 0.76 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for ResMed (RMD): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is ResMed (RMD), and what does it report?
Short answer · as of
ResMed is primarily a sleep and respiratory care business, not a general medical-instrument supplier. Demand comes through sleep clinics, home healthcare dealers and hospitals for therapy devices, ventilation equipment, diagnostics, masks, headgear and related accessories, while AirView, myAir and other connected tools support monitoring, adherence and provider workflows.
Research dated 2026-09-12.
Reporting pairs the dominant Sleep and Respiratory Care operation with SaaS. Brightree, MatrixCare and HEALTHCAREfirst extend the company into business management, care records, billing and analytics for organizations delivering care outside hospitals, but device-related revenue remains the larger economic engine.
What do the latest results show for ResMed (RMD)?
Research dated 2026-09-12.
Revenue reached a new high in the latest reported period, but gross profit, operating profit, net income and diluted earnings eased from the immediately preceding period. The top line therefore expanded without producing sequential profit growth, even as the longer annual record shows revenue and net income advancing throughout the displayed span and research spending rising alongside them.
Management expects annual revenue to keep growing, while warning of near-term gross-margin contraction and roughly flat operating-expense dollars. It also frames underlying seasonality after excluding the MatrixCare divestiture, the Noctrix acquisition and Astral revenue, so reported growth and underlying operating momentum may not move together cleanly.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $1.34B | $349M | $2.37 (diluted) |
| Q2 FY2026 | $1.42B | $393M | $2.68 (diluted) |
| Q3 FY2026 | $1.43B | $399M | $2.74 (diluted) |
| Q4 FY2026 | $1.46B | $383M | $2.64 (diluted) |
What are the financial strengths and risks for ResMed (RMD)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Positive operating cash flow across the displayed periods and cash above total debt give ResMed substantial financial flexibility. Cash has retreated from its recent peak but remains far above earlier levels in the series, while liquidity and distress screens indicate limited near-term balance-sheet strain.
The sharper risk sits in operating leverage rather than solvency. Profit measures fell sequentially despite higher revenue in the latest period, management expects gross-margin pressure, and the market value stands far above net cash; continued execution therefore matters more to the valuation than asset backing.
What should you watch next at ResMed (RMD)?
Short answer · as of
The next earnings report is expected on Jan 28, 2027.
Research dated 2026-09-12.
Revenue in the forthcoming report should be read against management’s annual growth range and its warning that normal seasonality is returning on an adjusted portfolio basis. The useful test is whether demand remains aligned with the longer growth path after separating MatrixCare, Noctrix and Astral effects.
Margin conversion deserves equal attention: compare gross profit with revenue, then check whether operating expenses remain near management’s indicated level. Recent earnings generally cleared expectations, but the latest sequential decline in profit makes the composition of the next result more informative than another headline beat.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does ResMed compare with its peers?
Short answer
ResMed's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
ResMed combines therapy hardware and replacement accessories with software that follows patients and devices after deployment. That differs from a pure equipment maker because AirView and myAir connect monitoring, setting adjustments, troubleshooting and adherence support to the installed therapy base.
The company also reaches beyond respiratory treatment through software for home medical equipment providers, pharmacies, senior living, skilled nursing, home health and hospice operators. SaaS broadens the workflow exposure, but Sleep and Respiratory Care remains much larger, so ResMed’s economics are still anchored in devices, masks and the channels that distribute them.
| Company | Price | Market value | Score |
|---|---|---|---|
| ResMed (RMD) — this page | $242.61 | $34.1B | 95 |
| $420.95 Nov 18, 2026 | $146B | 94 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $278.35 Nov 18, 2026 | $64.3B | 88 5-pillar Nov 18, 2026 | |
| $177.33 Nov 18, 2026 | $50.0B | 83 5-pillar Nov 18, 2026 | |
| $75.23 Nov 18, 2026 | $36.1B | 80 5-pillar Nov 18, 2026 | |
| $141.67 Nov 18, 2026 | $8.98B | 77 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $39.16 Nov 18, 2026 | $51.5B | 72 5-pillar Nov 18, 2026 | |
| $172.67 Nov 18, 2026 | $11.0B | 71 5-pillar Nov 18, 2026 | |
| $15.37 Nov 18, 2026 | $10.4B | 71 5-pillar Nov 18, 2026 | |
| $216.04 Nov 18, 2026 | $58.9B | 68 5-pillar Nov 18, 2026 | |
| $165.85 Nov 18, 2026 | $6.58B | 61 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $213.00 – $300.00
- Consensus target
- $246.89
- Median target
- $230.00
Consensus record · Captured .
Measured against a quoted price of $242.61 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 15 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 15
- Identified insiders
- 6
- Purchases
- 0
- Sales
- 1
- Other transactions
- 14
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RMD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RMD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ResMed (RMD)?
What Investors Ask About ResMed (RMD) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does ResMed sell besides sleep apnea machines?
ResMed sells masks, headgear, ventilation and diagnostic equipment, dental devices, connectivity modules and related accessories. It also supplies cloud software for patient management and operational workflows across home-based and post-acute care.
How do AirView and myAir fit ResMed’s device business?
AirView lets clinicians monitor connected devices and adjust settings remotely, while myAir gives sleep apnea patients education, troubleshooting and adherence support. Together they extend ResMed’s relationship with providers and patients beyond the initial device delivery.
How does the MatrixCare divestiture affect ResMed’s growth comparisons?
Management excludes the MatrixCare divestiture, along with the Noctrix acquisition and Astral revenue, when describing underlying seasonality. Reported revenue growth should therefore be separated from portfolio effects before judging demand momentum.
Can ResMed support its recently increased dividend from internal cash generation?
Operating cash flow has remained positive across the displayed periods, and cash exceeds total debt. The higher declared distribution therefore sits alongside strong liquidity and ongoing internal cash generation.
What is the RMD stock price today?
The last price recorded for ResMed Inc. (RMD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RMD price target?
The analyst consensus price target for ResMed Inc. (RMD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold RMD
Funds in our ETF coverage that list RMD among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LGHT ETF | 10.58% |